These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 35461768)
1. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity. Moriyama Y; Ishikane M; Ueno M; Matsunaga A; Ishizaka Y; Arashiro T; Kanno T; Suzuki T; Kimura K J Infect Chemother; 2022 Jul; 28(7):962-964. PubMed ID: 35461768 [TBL] [Abstract][Full Text] [Related]
2. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563 [TBL] [Abstract][Full Text] [Related]
4. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798 [TBL] [Abstract][Full Text] [Related]
5. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days. Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC Front Immunol; 2021; 12():786554. PubMed ID: 35003104 [TBL] [Abstract][Full Text] [Related]
7. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection. Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449 [TBL] [Abstract][Full Text] [Related]
8. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P Front Immunol; 2022; 13():909910. PubMed ID: 35784321 [TBL] [Abstract][Full Text] [Related]
9. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination. Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677 [TBL] [Abstract][Full Text] [Related]
10. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
11. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676 [TBL] [Abstract][Full Text] [Related]
17. Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. Yamamoto S; Maeda K; Matsuda K; Tanaka A; Horii K; Okudera K; Takeuchi JS; Mizoue T; Konishi M; Ozeki M; Sugiyama H; Aoyanagi N; Mitsuya H; Sugiura W; Ohmagari N Clin Infect Dis; 2022 Aug; 75(1):e683-e691. PubMed ID: 34950947 [TBL] [Abstract][Full Text] [Related]
18. Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers. Kitabatake M; Ouji-Sageshima N; Sonobe S; Furukawa R; Konda M; Hara A; Aoki H; Suzuki Y; Imakita N; Nakano A; Fujita Y; Shichino S; Nakano R; Ueha S; Kasahara K; Muro S; Yano H; Matsushima K; Ito T Jpn J Infect Dis; 2023 Jan; 76(1):72-76. PubMed ID: 36047181 [TBL] [Abstract][Full Text] [Related]
19. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery. Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127 [TBL] [Abstract][Full Text] [Related]
20. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level]. Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]